CN113796538A - Application of water-insoluble arabinoxylan in preparation of medicine or food for preventing cancer and improving natural killer cell immunocompetence - Google Patents
Application of water-insoluble arabinoxylan in preparation of medicine or food for preventing cancer and improving natural killer cell immunocompetence Download PDFInfo
- Publication number
- CN113796538A CN113796538A CN202110905917.6A CN202110905917A CN113796538A CN 113796538 A CN113796538 A CN 113796538A CN 202110905917 A CN202110905917 A CN 202110905917A CN 113796538 A CN113796538 A CN 113796538A
- Authority
- CN
- China
- Prior art keywords
- water
- arabinoxylan
- cells
- insoluble arabinoxylan
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920000617 arabinoxylan Polymers 0.000 title claims abstract description 65
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 title claims abstract description 64
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 54
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 27
- 235000013305 food Nutrition 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims description 16
- 201000011510 cancer Diseases 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 102000005962 receptors Human genes 0.000 claims description 14
- 108020003175 receptors Proteins 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 12
- 210000002865 immune cell Anatomy 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 241000196324 Embryophyta Species 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 8
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 108091008042 inhibitory receptors Proteins 0.000 claims description 8
- 238000001959 radiotherapy Methods 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 239000003513 alkali Substances 0.000 claims description 6
- 238000006073 displacement reaction Methods 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000004062 sedimentation Methods 0.000 claims description 6
- 230000022534 cell killing Effects 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 238000004820 blood count Methods 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000011033 desalting Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 235000021022 fresh fruits Nutrition 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 235000021581 juice product Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000011127 radiochemotherapy Methods 0.000 claims description 2
- 235000021067 refined food Nutrition 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 23
- 241000700605 Viruses Species 0.000 description 6
- 108091008877 NK cell receptors Proteins 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 4
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 3
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000005965 immune activity Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000027581 NK cell receptors Human genes 0.000 description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 2
- 102000004503 Perforin Human genes 0.000 description 2
- 108010056995 Perforin Proteins 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- HMFHBZSHGGEWLO-QMKXCQHVSA-N alpha-L-arabinofuranose Chemical group OC[C@@H]1O[C@@H](O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-QMKXCQHVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-KKQCNMDGSA-N beta-D-xylose Chemical group O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 150000004783 arabinoxylans Chemical class 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical group COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000447 pesticide residue Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Sustainable Development (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to an application of water-insoluble arabinoxylan in preparing medicines or foods for preventing cancers and improving the immunocompetence of natural killer cells.
Description
Technical Field
The invention relates to the technical field of medicines and foods, in particular to application of water-insoluble arabinoxylan in preparing medicines or foods for preventing cancers and improving the immunocompetence of natural killer cells.
Background
The arabinoxylan is formed by connecting a xylan main chain formed by connecting beta-D-xylopyranose residues through beta- (1-4) -glycosidic bonds and an a-L-arabinofuranosyl side chain. The beta-D-xylose residue can be independently substituted by alpha-L-arabinofuranose at C-2 and C-3, or can be doubly substituted by alpha-L-arabinofuranose at C-2 and C-3. The a-L-arabinofuranose side chain is formed by connecting 2 or more than 2 a-L-arabinofuranose monosaccharide molecules through 1-2, 1-3, 1-5 bonds, simultaneously contains a certain amount of ferulic acid group, and is covalently connected with arabinoxylan through an esterification mode. The lignin can also be linked to the side chains of arabinoxylans via ester or ether linkages. Arabinoxylan is the main component of plant cell wall hemicellulose in monocotyledons. The water-insoluble arabinoxylan has a high molecular weight and is a macromolecular plant polysaccharide second to cellulose.
Natural killer cells (NK) are important immune cells in the body and are important components in human body anti-tumor and microbial infection. Natural killer cells are MHC-free and therefore do not require antigen recognition and are antibody independent. Natural killer cells can release perforin and granzyme to perforate the cell surface, and granzyme enters target cells and then the target cells die. Simultaneously secretes a large amount of cytokines, directly acts on target cells or attacks the target cells by further activating other kinds of immune cells. Killing tumor cells, bacteria, viruses and other microbial infections. Simultaneously, the immune cells and dendritic cells, macrophages, T cells and the like participate in various immune activities of human bodies together. Research shows that natural killer cells can participate in improving the hematopoietic function of human bodies, buffering immune rejection after organ transplantation, improving the anti-tumor and anti-infection capacity and relieving autoimmune disorder. Natural killer cell surfaces have a variety of protein receptors that regulate their dynamics, including killer cell activating receptors (KAR) and killer cell inhibiting receptors (KIR). To avoid false attack of natural killer cells on healthy cells, natural killer cells are generally in a suppressed state. In tumor patients, sub-health disease patients and hypersensitive patients, the inhibition signals of natural killer cells are relieved by reducing the inhibition of the natural killer cells, so that the activity of the natural killer cells can be released, and the autoimmune capacity is improved.
The application of water-insoluble arabinoxylan in preventing cancer and improving the immune activity of natural killer cells is not reported.
Disclosure of Invention
The invention provides application of water-insoluble arabinoxylan in preparation of medicines or foods for preventing cancers and improving natural killer cell immunocompetence, and specifies medicines or foods for preventing cancers and improving natural killer cell immunocompetence, which are prepared from water-insoluble arabinoxylan, so that the cancers can be effectively prevented and the immunocompetence of natural killer cells can be improved.
Application of water-insoluble arabinoxylan in preparing medicine or food for preventing cancer and improving natural killer cell immunocompetence is provided.
Use of water-insoluble arabinoxylan in the preparation of intestinal tract-acting immunostimulant is provided.
Further, the molecular weight of the polysaccharide in the water-insoluble arabinoxylan is 15 to 22 ten thousand.
Further, the use of the water-insoluble arabinoxylan for the preparation of a medicament or food product having any one of the following effects: (1) improving the number and activity of immune cells of an organism; (2) the body can automatically recover the white blood cell count in the auxiliary chemoradiotherapy stage; (3) reducing side effects caused by radiotherapy and chemotherapy; (4) reduce the recurrence and metastasis of tumor.
Further, the use of the water-insoluble arabinoxylan for the preparation of a medicament or food product having any one of the following effects: a) the number of NK cells of the human body is increased; b) increasing NK cell killing power; c) increasing activating receptor activity of NK cells; d) reducing inhibitory receptor activity of NK cells.
In the present invention, the NK cell killing includes, but is not limited to, the ability of NK cells to kill tumor cells, tumor stem cells, viruses, and senescent cells; activating receptors for said NK cells include, but are not limited to, NKG2D, NKp30, NKp44, NKp 46; such inhibitory receptors include, but are not limited to, KIR 1.
In the invention, the water-insoluble arabinoxylan is prepared by carrying out alkali liquor leaching, dealkalization, separation and purification on plant raw materials after pretreatment and impurity removal.
Further, the preparation method of the water-insoluble arabinoxylan of the present invention comprises the following steps:
crushing plant raw materials, adding 8-12 times of NaOH solution with the weight and the mass concentration of 0.2-1.0%, carrying out heat preservation treatment at 40-90 ℃ for 1.5-2.5 h, replacing and washing with clear water, and filtering and dehydrating to obtain clean fibers;
step two, adding 6-10 times of NaOH solution with the weight and the mass concentration of 8-12% into the obtained clean fiber, performing heat preservation extraction at 55-65 ℃ for 5.5-6.5 h, performing sedimentation centrifugation to collect primary supernatant, performing continuous countercurrent displacement on the residue by using 8-12 times of NaOH solution with the mass concentration of 3-5%, performing sedimentation centrifugation on displacement solution, collecting secondary supernatant, and combining the primary supernatant and the secondary supernatant to obtain the arabinoxylan alkali solution;
step three, after dealkalization treatment, adding acid to neutralize the solution until the pH value is 6.0-8.0, concentrating and dehydrating, adding clear water to perform continuous replacement desalting treatment, and drying to obtain the araboxylan;
and step four, separating and purifying the obtained arabinoxylan to obtain the water-insoluble arabinoxylan.
The water-insoluble arabinoxylan can be used as a single component or used as a compound component, and can be selectively added with conventional auxiliary materials to be prepared into granules, powder, tablets, capsules or suspensions according to a conventional process, and the granules, the powder, the tablets, the capsules or the suspensions can be used as medicines, common foods or health-care foods.
The water-insoluble arabinoxylan can be added into any other processed food or food raw material independently or as a compound component, and can play a role through different food carriers; the different food carriers comprise rice, flour products, dairy products, vegetable protein products, dry and fresh fruit juice products, solid beverages, instant beverages and the like.
Compared with the prior art, the invention has the following beneficial effects:
1. the water-insoluble arabinoxylan is obtained by physical centrifugal extraction, the molecular weight is up to 15-22 ten thousand, the molecular weight of the arabinoxylan prepared by enzymatic hydrolysis is only less than 1 ten thousand, compared with the arabinoxylan prepared by enzymatic hydrolysis, the water-insoluble arabinoxylan keeps natural macromolecular characteristics of the arabinoxylan, such as the molecular weight, the structure stability, the molecular chain length and the like, cannot be hydrolyzed in small intestine by endogenous enzyme systems of human bodies, can be digested by microorganisms in large intestine sections, and can be conveyed to colorectal parts where microorganisms at the tail end of the intestine are most enriched, the water-insoluble arabinoxylan acts on intestinal flora and metabolizes specific products, and the effects of preventing cancers and improving the immunocompetence of natural killer cells are achieved through the specific products.
2. The water-insoluble arabinoxylan can improve the division number of human NK cells, improve the lethality of the NK cells, improve the activity of activated receptors of the NK cells and reduce the activity of inhibitory receptors; other lymphocyte and immune cell activities are regulated by cytokines and chemokines; has effects in increasing the number and activity of immune cells; the immunity of a tumor patient in the radiotherapy and chemotherapy stage is assisted to be rapidly improved, the white blood cell count is automatically recovered, and the white blood is assisted to be increased; the side effects of the tumor patients caused by radiotherapy and chemotherapy in the radiotherapy and chemotherapy stage are reduced; reducing the recurrence and metastasis of tumor.
Detailed Description
The invention provides an application of water-insoluble arabinoxylan in preparing medicines or foods for preventing cancers and improving the immunocompetence of natural killer cells.
The invention provides application of water-insoluble arabinoxylan in preparing an immune promoter acting on intestinal tracts. Different from the effect that water-soluble arabinoxylan enters blood to play, the water-insoluble arabinoxylan provided by the invention is used as a carbohydrate which can be fermented by intestinal flora, and is decomposed and metabolized by the flora in the intestinal tract to promote the immunity of the organism.
In the present invention, the molecular weight of the polysaccharide in the water-insoluble arabinoxylan is 15 to 22 ten thousand. The water-insoluble arabinoxylan can be decomposed and utilized by intestinal microorganisms to generate metabolites with anti-tumor characteristics and natural killer cell immunocompetence improving functions, so that the effects of preventing cancers and improving the immunity of organisms are achieved.
Use of the water-insoluble arabinoxylan for the preparation of a medicament or food product having any one of the following effects: (1) improving the number and activity of immune cells of an organism; (2) the immunity of a tumor patient in the radiotherapy and chemotherapy stage is assisted to be rapidly improved, the white blood cell count is automatically recovered, and the white blood is assisted to be increased; (3) the side effects of the tumor patients caused by radiotherapy and chemotherapy in the radiotherapy and chemotherapy stage are reduced; (4) reduce the recurrence and metastasis of tumor.
Further, the use of the water-insoluble arabinoxylan for the preparation of a medicament or food product having any one of the following effects: a) the number of NK cells of the human body is increased; b) increasing NK cell killing power; c) increasing activating receptor activity of NK cells; d) reducing inhibitory receptor activity of NK cells; e) other lymphocyte and immune cell activities are regulated by cytokines and chemokines.
In the present invention, the NK cell killing includes, but is not limited to, the ability of NK cells to kill tumor cells, tumor stem cells, viruses, and senescent cells; activating receptors for said NK cells include, but are not limited to, NKG2D, NKp30, NKp44, NKp 46; such inhibitory receptors include, but are not limited to, KIR 1.
In the invention, the water-insoluble arabinoxylan is prepared by carrying out alkali liquor leaching, dealkalization, separation and purification on plant raw materials after pretreatment and impurity removal.
Further, the preparation method of the water-insoluble arabinoxylan of the present invention comprises the following steps:
crushing plant raw materials, adding 8-12 times of NaOH solution with the weight and the mass concentration of 0.2-1.0%, carrying out heat preservation treatment at 40-90 ℃ for 1.5-2.5 h, replacing and washing with clear water, and filtering and dehydrating to obtain clean fibers;
step two, adding 6-10 times of NaOH solution with the weight and the mass concentration of 8-12% into the obtained clean fiber, performing heat preservation extraction at 55-65 ℃ for 5.5-6.5 h, performing sedimentation centrifugation to collect primary supernatant, performing continuous countercurrent displacement on the residue by using 8-12 times of NaOH solution with the mass concentration of 3-5%, performing sedimentation centrifugation on displacement solution, collecting secondary supernatant, and combining the primary supernatant and the secondary supernatant to obtain the arabinoxylan alkali solution;
step three, after dealkalization treatment, adding acid to neutralize the solution until the pH value is 6.0-8.0, concentrating and dehydrating, adding clear water to perform continuous replacement desalting treatment, and drying to obtain the araboxylan;
and step four, separating and purifying the obtained arabinoxylan to obtain the water-insoluble arabinoxylan.
In the third step of the preparation method of the water-insoluble arabinoxylan, the clear water is continuously replaced and desalted, so that harmful substances from raw materials in the product can be fully removed; the drying may be concentrated spray drying.
The separation and purification in the fourth step of the preparation method of the water-insoluble arabinoxylan is specifically centrifugal treatment. And (3) obtaining the water-insoluble arabinoxylan by centrifugation according to the molecular weight difference between the water-soluble arabinoxylan and the water-insoluble xylan and the solubility difference in water. Compared with water-soluble arabinoxylan, the water-insoluble arabinoxylan has a higher molecular weight, cannot be dissolved in water, can only form a suspension for a short time, and precipitates to the bottom after a certain time. According to different movement modes of substances with different molecular weights and different specific gravities under the action of centrifugal force, by high-speed butterfly centrifugation, small molecular substances such as heavy metals, pesticide residues, water-soluble inorganic salts, mycotoxins and the like in raw materials can be effectively removed, and the high-purity water-insoluble arabinoxylan is obtained.
In clinical application, the immune function evaluation and the natural killer cell immune activity evaluation are carried out through cytokine detection, NK cell receptor detection, 107a experiments and the like.
And (3) detecting cytokines: the cytokines are mainly derived from factors secreted by NK cells of the body, CD8+ CTL/CD8+ T cells and CD4+ T cells. The detection of the expression of the cell factor can effectively evaluate the immune function and the capability of the organism to defend bacteria, viruses, inflammations and cancer cells, can also effectively analyze the killing capability of NK cells and CTL cells to the bacteria, the viruses and the cancer cells, and guides personalized and individualized immunity regulation medication.
Detection of NK cell receptors: NK cell receptors include inhibitory receptors (KIR) and activated receptors (KAR) and recognition receptors, and the inhibitory receptors and the activated receptors in healthy people are not in a dynamic equilibrium state under the related relationship and action of NK and CTL when subjected to factors such as inflammation, environment, radiation and the like. The expression of a recognition receptor NKG2D is reduced, the expression increase of receptor ploidy NKG2A/CD94 is inhibited, NKG2D on the surface of a CTL cell is lost or shed, and the self-limited expression increase of MHC-1 is combined with KIR to play an inhibiting role, so that the immunosuppression of the organism is easily caused, and target cells (bacteria, viruses, cancer cells and the like) cannot be recognized by the NK cell and the CTL cell to cause the immune imbalance and the uncontrolled state of the organism. The NK cell receptor can be analyzed to effectively evaluate the recognition and killing capability of the NK cell receptor on the target cells.
107a experiment: when NK cells and CTL cells kill target cells, CD107a molecules are transported to the cell membrane surface as degranulation occurs, and the up-regulation of CD107a molecules is consistent with the secretion of perforin, the expression level of which is significantly correlated with the killing activity of NK cells and CTL cells. Therefore, NK cells and CTL cells positively expressed by the CD107a molecule can represent NK cells and CTL cells with killing activity.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are included in the scope of the present invention.
Claims (9)
1. Application of water-insoluble arabinoxylan in preparing medicine or food for preventing cancer and improving natural killer cell immunocompetence is provided.
2. Use of water-insoluble arabinoxylan in the preparation of intestinal tract-acting immunostimulant is provided.
3. Use according to claim 1 or 2, wherein the water-insoluble arabinoxylan has a glycan molecular weight of from 15 to 22 ten thousand.
4. Use according to claim 1, wherein the water-insoluble arabinoxylan is used for the preparation of a pharmaceutical or food product having any one of the following effects:
(1) improving the number and activity of immune cells of an organism;
(2) the body can automatically recover the white blood cell count in the auxiliary chemoradiotherapy stage;
(3) reducing side effects caused by radiotherapy and chemotherapy;
(4) reduce the recurrence and metastasis of tumor.
5. Use according to claim 1, wherein the water-insoluble arabinoxylan is used for the preparation of a pharmaceutical or food product having any one of the following effects:
a) the number of NK cells of the human body is increased;
b) increasing NK cell killing power;
c) increasing activating receptor activity of NK cells;
d) reducing inhibitory receptor activity of NK cells;
e) other lymphocyte and immune cell activities are regulated by cytokines and chemokines.
6. The use of claim 1 or 2, wherein the water-insoluble arabinoxylan is prepared by pre-treating a plant raw material to remove impurities, leaching with an alkali solution, dealkalizing, separating and purifying.
7. Use according to claim 6, characterized in that the preparation process of the water-insoluble arabinoxylan comprises the following steps:
crushing plant raw materials, adding 8-12 times of NaOH solution with the weight and the mass concentration of 0.2-1.0%, carrying out heat preservation treatment at 40-90 ℃ for 1.5-2.5 h, replacing and washing with clear water, and filtering and dehydrating to obtain clean fibers;
step two, adding 6-10 times of NaOH solution with the weight and the mass concentration of 8-12% into the obtained clean fiber, performing heat preservation extraction at 55-65 ℃ for 5.5-6.5 h, performing sedimentation centrifugation to collect primary supernatant, performing continuous countercurrent displacement on the residue by using 8-12 times of NaOH solution with the mass concentration of 3-5%, performing sedimentation centrifugation on displacement solution, collecting secondary supernatant, and combining the primary supernatant and the secondary supernatant to obtain the arabinoxylan alkali solution;
step three, after dealkalization treatment, adding acid to neutralize the solution until the pH value is 6.0-8.0, concentrating and dehydrating, adding clear water to perform continuous replacement desalting treatment, and drying to obtain the araboxylan;
and step four, separating and purifying the obtained arabinoxylan to obtain the water-insoluble arabinoxylan.
8. The use of the water-insoluble arabinoxylan according to claims 1 to 7, wherein the water-insoluble arabinoxylan is used as a drug, a general food or a health food, and is prepared into granules, powder, tablets, capsules or suspensions by a conventional process, wherein the conventional excipients are selectively added into the water-insoluble arabinoxylan or the components of the complex.
9. Use according to claim 1 or 8, characterized in that the water-insoluble arabinoxylan is added to any other processed food or food material, alone or as a component of a complex, functioning through different food carriers; the different food carriers comprise rice, flour products, dairy products, vegetable protein products, dry and fresh fruit juice products, solid beverages and instant beverages.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110905917.6A CN113796538A (en) | 2021-08-06 | 2021-08-06 | Application of water-insoluble arabinoxylan in preparation of medicine or food for preventing cancer and improving natural killer cell immunocompetence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110905917.6A CN113796538A (en) | 2021-08-06 | 2021-08-06 | Application of water-insoluble arabinoxylan in preparation of medicine or food for preventing cancer and improving natural killer cell immunocompetence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113796538A true CN113796538A (en) | 2021-12-17 |
Family
ID=78942838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110905917.6A Withdrawn CN113796538A (en) | 2021-08-06 | 2021-08-06 | Application of water-insoluble arabinoxylan in preparation of medicine or food for preventing cancer and improving natural killer cell immunocompetence |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113796538A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140127179A1 (en) * | 2012-11-02 | 2014-05-08 | Scientific Formulations, Llc | Natural Killer Cell Formulations |
| US20180325156A1 (en) * | 2015-10-26 | 2018-11-15 | Kyonggi University Industry & Academia Cooperation Foundation | Immune-enhancing composition comprising arabinoxylan from corn or corn processing by-product |
| CN112691115A (en) * | 2021-02-01 | 2021-04-23 | 上海赛普瑞特生物科技有限公司 | Arabinoxylan and compound for preventing/treating gastrointestinal mucosa and liver injury |
-
2021
- 2021-08-06 CN CN202110905917.6A patent/CN113796538A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140127179A1 (en) * | 2012-11-02 | 2014-05-08 | Scientific Formulations, Llc | Natural Killer Cell Formulations |
| US20180325156A1 (en) * | 2015-10-26 | 2018-11-15 | Kyonggi University Industry & Academia Cooperation Foundation | Immune-enhancing composition comprising arabinoxylan from corn or corn processing by-product |
| CN112691115A (en) * | 2021-02-01 | 2021-04-23 | 上海赛普瑞特生物科技有限公司 | Arabinoxylan and compound for preventing/treating gastrointestinal mucosa and liver injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Composition, isolation, purification and biological activities of Sargassum fusiforme polysaccharides: A review | |
| Lam et al. | Non-digestible long chain beta-glucans as novel prebiotics | |
| US20060024328A1 (en) | Potent immunostimulatory extracts from microalgae | |
| AU2017230150B2 (en) | Edible bird's nest extract and method of extraction | |
| JP5154964B2 (en) | Contains royal jelly-degrading enzyme | |
| KR20130077802A (en) | The preparing method of immune improving agents | |
| KR101696076B1 (en) | A polysaccharide having improved immuno-activity from Enteromorpha prolifera and preparation method thereof | |
| US20170290853A1 (en) | Methods to facilitate the solubilization of beta-1,3-glucan and enhance immune function and other related uses | |
| CN104017098A (en) | Method for directly extracting lentinus-edodes active polysaccharide from waste lentinus-edodes sticks | |
| KR20200074978A (en) | Method for preparing pectic polysaccharide isolate enriched in rhamnogalacturonan-I | |
| JP2011026525A (en) | METHOD FOR EXTRACTING POLYSACCHARIDE COMPRISING beta-GLUCAN AS MAIN COMPONENT | |
| EA034017B1 (en) | Methods based on cultivating bacillus coagulans mtcc 5856 in the presence of natural plant fibers | |
| US20120124703A1 (en) | Novel coprinus comatus and tremella mesenterica mushroom strains, products and extracts thereof and compositions comprising them | |
| CN113796538A (en) | Application of water-insoluble arabinoxylan in preparation of medicine or food for preventing cancer and improving natural killer cell immunocompetence | |
| AU2017277413A1 (en) | Euglena lysate composition and method for producing the composition and a purified beta-1,3-glucan | |
| CN102987408B (en) | Method for extracting nutritional ingredients such as free amino acids from waste cordyceps militaris cocoons | |
| JP2014221899A (en) | METHOD FOR EXTRACTING POLYSACCHARIDE COMPRISING β-GLUCAN AS MAIN COMPONENT | |
| US9901606B2 (en) | Euglena lysate composition | |
| CN115261414A (en) | Method for preparing tremella fermentation liquor by combining compound enzyme with microbial fermentation | |
| Wu | Polysaccharide-protein complexes from edible fungi and applications | |
| CN102987405A (en) | Method for preparing health food capsules by using cordyceps militaris and cocoon extracts | |
| KR101737626B1 (en) | Composition for immunosuppression comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| CN115260280B (en) | Pepper seed antibacterial peptide and preparation method and application thereof | |
| RU2393228C2 (en) | Food fibre manufacturing technique | |
| JP4422404B2 (en) | Infection prevention / treatment agent and food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20211217 |
|
| WW01 | Invention patent application withdrawn after publication |